Deep generative models design mRNA sequences with enhanced translational capacity and stability
Clinical Snapshot
PICO Framework
| P — Population | In vitro cell culture systems and laboratory mice (C57BL/6 and BALB/c strains) |
| I — Intervention | GEMORNA-designed mRNA sequences with optimized coding sequences and untranslated regions |
| C — Comparator | Conventional optimized mRNA sequences and benchmark controls |
| O — Outcomes | mRNA expression levels (luciferase, erythropoietin), protein translation efficiency, mRNA stability, antibody responses, and circular RNA expression |
Bottom Line
This preclinical study demonstrates that AI-designed mRNA sequences can achieve substantial improvements in protein expression and stability compared to conventional approaches. The GEMORNA platform showed impressive effect sizes with up to 41-fold increases in reporter protein expression and enhanced therapeutic protein production. While these results are promising for advancing mRNA therapeutics beyond COVID-19 vaccines, the findings require validation in human clinical trials. The technology could potentially improve treatment efficacy for protein replacement therapies and enhance vaccine responses. However, clinicians should await safety and efficacy data from human studies before considering clinical applications. The approach represents an important advancement in biotechnology that may eventually translate to improved patient outcomes in mRNA-based treatments.
Key Findings
P Value: Not reported in abstract
Effect Size: Up to 41-fold increase in luciferase expression, 15-fold increase in erythropoietin expression
Primary Outcome: Enhanced mRNA expression and protein translation efficiency
Nnt Or Sensitivity: Effect sizes suggest high sensitivity for detecting enhanced mRNA performance
Confidence Interval: Not reported in abstract
Clinical Application
Requires significant clinical development and regulatory approval before implementation Relevant to TGA regulatory pathway for novel mRNA therapeutics; potential applications in PBS-listed treatments for conditions requiring protein replacement therapy Patients requiring mRNA-based therapeutics, particularly for protein replacement therapy and vaccination
Abstract
Despite the success of messenger RNA (mRNA) COVID-19 vaccines, extending this modality to more diseases necessitates substantial enhancements. We present GEMORNA, a generative RNA model that uses transformer architectures tailored for mRNA coding sequences (CDSs) and untranslated regions (UTRs) to design mRNAs with enhanced expression and stability. GEMORNA-designed full-length mRNAs exhibited up to a 41-fold increase in firefly luciferase expression compared with an optimized benchmark in vitro. GEMORNA-generated therapeutic mRNAs achieved up to a 15-fold enhancement in human erythropoietin (EPO) expression and substantially elicited antibody titers of COVID vaccine in mice. Additionally, GEMORNA's versatility extends to circular RNA, substantially enhancing circular EPO expression and boosting antitumor cytotoxicity in chimeric antigen receptor T cells. These advancements highlight the vast potential of deep generative artificial intelligence for mRNA therapeutics.
References
- 1.Zhang, H., Liu, H., Xu, Y., Huang, H., Liu, Y., Wang, J., Qin, Y., Wang, H., Ma, L., Xun, Z., Hou, X., Lu, T. K., & Cao, J. (2025). Deep generative models design mRNA sequences with enhanced translational capacity and stability. Science. https://doi.org/10.1126/science.adr8470
Related Research
CPT: pharmacometrics & systems pharmacology
Structured Schemas for Provenance-Rich, LLM-Assisted QSP Model Calibration
2 Aug 2026
Journal of pharmacokinetics and pharmacodynamics
Diffusion models for virtual populations and pharmacometric simulations
1 Aug 2026
Journal of chemical information and modeling
HyperDC: A Non-Uniform Hypergraph Framework for Dual- and Higher-Order Drug Combination Recommendation Across Diverse Complex Diseases
29 July 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service